^
    Back
    Association details:
    Biomarker:BRAF K601E
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Case Rep Oncol
    Title:

    Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation

    Excerpt:
    We administered single-agent vemurafenib to a melanoma patient carrying BRAF K601E mutation as the first-line treatment. Unfortunately, this therapy did not result in a tumor response.
    DOI:
    10.1159/000500481